Statinotherapy – the paradigm of prevention and treatment of atherosclerotic pathology (focus on atorvastatin)
The authors discuss statinotherapy perspectives for secondary prevention, emphasizing statins’ effectiveness due to their high hypolipidemic activity and multiple pleiotropic effects. Aim. To study hypolipidemic activity and safety of generic atorvastatin (Liptonorm®), in comparison to original ator...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2006-12-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1411 |
| _version_ | 1797882781211033600 |
|---|---|
| author | R. G. Oganov D. M. Aronov M. G. Bubnova |
| author_facet | R. G. Oganov D. M. Aronov M. G. Bubnova |
| author_sort | R. G. Oganov |
| collection | DOAJ |
| description | The authors discuss statinotherapy perspectives for secondary prevention, emphasizing statins’ effectiveness due to their high hypolipidemic activity and multiple pleiotropic effects. Aim. To study hypolipidemic activity and safety of generic atorvastatin (Liptonorm®), in comparison to original atorvastatin, Liprimar®. Material and methods. Thirty patients with coronary heart disease (CHD) and hypercholesterolemia (HCH) were randomized to 12-week original or generic atorvastatin treatment. Blood lipids, hepatic enzymes, and kreatine phosphokinase levels were measured. Results. Total cholesterol (TCH) levels in Liptonorm® and Liprimar® groups reduced from 7,7±1,25 to 4,4±0,8 mmol/l and from 6,9±1,3 to 4,6±0,7 mmol/l, respectively; low-density lipoprotein CH levels reduced from 5,4±1,4 to 2,7±0,7 mmol/l and from 4,7±1,3 to 2,7±0,7 mmol/l, respectively; triglycerides’ levels reduced from 1,7±0,7 to 1,2±0,3 mmol/l and from 1,9±1,0 to 1,2±0,4 mmol/l, respectively. High-density lipoprotein CH levels increased from 1,03±0,25 to 1,13±0,21 mmol/l and from 1,32±0,31 to 1,37±0,28 mmol/l, respectively. Lipid profile dynamics throughout the study was significant and similar in both groups; enzyme levels remained virtually Conclusion. Atorvastatin generic Liptonorm® demonstrated blood lipid effects similar to those for original atorvastatin. |
| first_indexed | 2024-04-10T03:40:15Z |
| format | Article |
| id | doaj.art-fb1730cab09148cdb5b5b09dca5bf8c2 |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2024-04-10T03:40:15Z |
| publishDate | 2006-12-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-fb1730cab09148cdb5b5b09dca5bf8c22023-03-13T07:23:13Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252006-12-0156951071121Statinotherapy – the paradigm of prevention and treatment of atherosclerotic pathology (focus on atorvastatin)R. G. Oganov0D. M. Aronov1M. G. Bubnova2Государственный научно-исследовательский центр профилактической медицины Росздрава. МоскваГосударственный научно-исследовательский центр профилактической медицины Росздрава. МоскваГосударственный научно-исследовательский центр профилактической медицины Росздрава. МоскваThe authors discuss statinotherapy perspectives for secondary prevention, emphasizing statins’ effectiveness due to their high hypolipidemic activity and multiple pleiotropic effects. Aim. To study hypolipidemic activity and safety of generic atorvastatin (Liptonorm®), in comparison to original atorvastatin, Liprimar®. Material and methods. Thirty patients with coronary heart disease (CHD) and hypercholesterolemia (HCH) were randomized to 12-week original or generic atorvastatin treatment. Blood lipids, hepatic enzymes, and kreatine phosphokinase levels were measured. Results. Total cholesterol (TCH) levels in Liptonorm® and Liprimar® groups reduced from 7,7±1,25 to 4,4±0,8 mmol/l and from 6,9±1,3 to 4,6±0,7 mmol/l, respectively; low-density lipoprotein CH levels reduced from 5,4±1,4 to 2,7±0,7 mmol/l and from 4,7±1,3 to 2,7±0,7 mmol/l, respectively; triglycerides’ levels reduced from 1,7±0,7 to 1,2±0,3 mmol/l and from 1,9±1,0 to 1,2±0,4 mmol/l, respectively. High-density lipoprotein CH levels increased from 1,03±0,25 to 1,13±0,21 mmol/l and from 1,32±0,31 to 1,37±0,28 mmol/l, respectively. Lipid profile dynamics throughout the study was significant and similar in both groups; enzyme levels remained virtually Conclusion. Atorvastatin generic Liptonorm® demonstrated blood lipid effects similar to those for original atorvastatin.https://cardiovascular.elpub.ru/jour/article/view/1411ишемическая болезнь сердцавторичная профилактикааторвастатинплейотропные эффекты |
| spellingShingle | R. G. Oganov D. M. Aronov M. G. Bubnova Statinotherapy – the paradigm of prevention and treatment of atherosclerotic pathology (focus on atorvastatin) Кардиоваскулярная терапия и профилактика ишемическая болезнь сердца вторичная профилактика аторвастатин плейотропные эффекты |
| title | Statinotherapy – the paradigm of prevention and treatment of atherosclerotic pathology (focus on atorvastatin) |
| title_full | Statinotherapy – the paradigm of prevention and treatment of atherosclerotic pathology (focus on atorvastatin) |
| title_fullStr | Statinotherapy – the paradigm of prevention and treatment of atherosclerotic pathology (focus on atorvastatin) |
| title_full_unstemmed | Statinotherapy – the paradigm of prevention and treatment of atherosclerotic pathology (focus on atorvastatin) |
| title_short | Statinotherapy – the paradigm of prevention and treatment of atherosclerotic pathology (focus on atorvastatin) |
| title_sort | statinotherapy the paradigm of prevention and treatment of atherosclerotic pathology focus on atorvastatin |
| topic | ишемическая болезнь сердца вторичная профилактика аторвастатин плейотропные эффекты |
| url | https://cardiovascular.elpub.ru/jour/article/view/1411 |
| work_keys_str_mv | AT rgoganov statinotherapytheparadigmofpreventionandtreatmentofatheroscleroticpathologyfocusonatorvastatin AT dmaronov statinotherapytheparadigmofpreventionandtreatmentofatheroscleroticpathologyfocusonatorvastatin AT mgbubnova statinotherapytheparadigmofpreventionandtreatmentofatheroscleroticpathologyfocusonatorvastatin |